These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33978269)

  • 21. Clopidogrel-Related High Residual Platelet Reactivity Associated with Estimated Glomerular Filtration Rate in Patients with Acute Ischemic Stroke.
    Zhang Y; Zong Y; Liu J; Yin K; Wang Y; Bian Y; Huang Y; Liu W; Cao Y
    Cerebrovasc Dis Extra; 2023; 13(1):83-89. PubMed ID: 37812922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE).
    Alfredsson J; Lindahl TL; Gustafsson KM; Janzon M; Jonasson L; Logander E; Nilsson L; Swahn E
    Thromb Res; 2015 Aug; 136(2):335-40. PubMed ID: 26033398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G
    J Thromb Thrombolysis; 2016 Aug; 42(2):245-53. PubMed ID: 26951167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet reactivity in patients with chronic kidney disease undergoing percutaneous coronary intervention.
    Zhu P; Tang XF; Xu JJ; Song Y; Liu R; Zhang Y; Gao L; Gao Z; Chen J; Yang YJ; Gao RL; Xu B; Yuan JQ
    Platelets; 2019; 30(7):901-907. PubMed ID: 30518271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.
    Verdoia M; Rolla R; Negro F; Tonon F; Pergolini P; Nardin M; Marcolongo M; De Luca G;
    Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):292-299. PubMed ID: 31780401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Drugs Ther; 2015; 29(5):443-50. PubMed ID: 26428927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Barbieri L; Marino P; Carriero A; Suryapranata H; De Luca G;
    J Cardiol; 2019 Mar; 73(3):198-203. PubMed ID: 30522897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
    Zhao Z; Ma M; Huang X; Sun T; Han K; Yang S; Zhou Y
    Front Immunol; 2022; 13():969984. PubMed ID: 36248871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Tonon F; Kedhi E; Suryapranata H; Carriero A; De Luca G;
    J Thromb Thrombolysis; 2019 Oct; 48(3):413-421. PubMed ID: 31065927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study.
    Valenti R; Marcucci R; Capodanno D; De Luca G; Migliorini A; Gori AM; Parodi G; Giusti B; Carrabba N; Paniccia R; Cantini G; Marrani M; Gensini GF; Abbate R; Antoniucci D
    J Thromb Thrombolysis; 2015 Jul; 40(1):76-82. PubMed ID: 25502874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
    Chong Tou TJ; Liu PM; Wang JF; Sio Cham ZC; O U YF; Lei Sio ZW; Lei Put PZ; Lei Sok SM; Zhou SX; Wu W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Feb; 44(2):138-43. PubMed ID: 26926507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Marino P; Bellomo G; Kedhi E; Suryapranata H; Carriero A; De Luca G;
    Pharmacol Res; 2018 Mar; 129():27-33. PubMed ID: 29355684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor.
    Verdoia M; Tonon F; Gioscia R; Nardin M; Fierro N; Sagazio E; Negro F; Pergolini P; Rolla R; De Luca G;
    Thromb Res; 2020 Dec; 196():231-237. PubMed ID: 32916566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
    Tsoumani ME; Tatsidou PT; Ntalas IV; Goudevenos JA; Tselepis AD
    Platelets; 2016 Dec; 27(8):812-820. PubMed ID: 27337147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus.
    Valenti R; Cantini G; Marcucci R; Marrani M; Migliorini A; Carrabba N; Comito V; Vergara R; Cerisano G; Parodi G; Abbate R; Gori AM; Gensini GF; Antoniucci D
    Int J Cardiol; 2015 Dec; 201():561-7. PubMed ID: 26334380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting.
    Guo LZ; Kim MH; Shim CH; Choi SY; Serebruany VL
    Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):145-51. PubMed ID: 27533756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
    Harding SA; Holley A; Wilkins B; Fairley S; Simmonds M; Larsen PD
    Intern Med J; 2017 Nov; 47(11):1298-1305. PubMed ID: 28857445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.